AKERO THERAPEUTICS, INC 00973Y108 US00973Y1082 12/02/2025 To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger. SECTION 14A SAY-ON-PAY VOTES ISSUER 32193 0 FOR 32193 FOR 1 AKERO THERAPEUTICS, INC 00973Y108 US00973Y1082 12/02/2025 To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger. SECTION 14A SAY-ON-PAY VOTES ISSUER 32193 0 FOR 32193 FOR 2 AKERO THERAPEUTICS, INC 00973Y108 US00973Y1082 12/02/2025 To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger. SECTION 14A SAY-ON-PAY VOTES ISSUER 71655 0 FOR 71655 FOR 1 AKERO THERAPEUTICS, INC 00973Y108 US00973Y1082 12/02/2025 To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger. SECTION 14A SAY-ON-PAY VOTES ISSUER 71655 0 FOR 71655 FOR 2 AMYLYX PHARMACEUTICALS, INC. 03237H101 US03237H1014 06/04/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 531624 0 FOR 531624 FOR 1 AMYLYX PHARMACEUTICALS, INC. 03237H101 US03237H1014 06/04/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 531624 0 FOR 531624 FOR 2 AMYLYX PHARMACEUTICALS, INC. 03237H101 US03237H1014 06/04/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1031978 0 FOR 1031978 FOR 1 AMYLYX PHARMACEUTICALS, INC. 03237H101 US03237H1014 06/04/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1031978 0 FOR 1031978 FOR 2 ANNEXON, INC. 03589W102 US03589W1027 06/11/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 907026 0 FOR 907026 FOR 1 ANNEXON, INC. 03589W102 US03589W1027 06/11/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 907026 0 FOR 907026 FOR 2 ANNEXON, INC. 03589W102 US03589W1027 06/11/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1760699 0 FOR 1760699 FOR 1 ANNEXON, INC. 03589W102 US03589W1027 06/11/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1760699 0 FOR 1760699 FOR 2 APOGEE THERAPEUTICS, INC. 03770N101 US03770N1019 06/09/2026 Approval, on a non-binding advisory basis, of the compensation of our named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 1 0 FOR 1 FOR 1 APOGEE THERAPEUTICS, INC. 03770N101 US03770N1019 06/09/2026 Approval, on a non-binding advisory basis, of the compensation of our named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 1 0 FOR 1 FOR 2 COMPASS THERAPEUTICS, INC. 20454B104 US20454B1044 06/10/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 458989 11 ABSTAIN 458989 AGAINST 1 COMPASS THERAPEUTICS, INC. 20454B104 US20454B1044 06/10/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 458989 11 ABSTAIN 458989 AGAINST 2 COMPASS THERAPEUTICS, INC. 20454B104 US20454B1044 06/10/2026 To approve, on a non-binding, advisory basis, the holding of future advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 458989 11 ABSTAIN 458989 AGAINST 1 COMPASS THERAPEUTICS, INC. 20454B104 US20454B1044 06/10/2026 To approve, on a non-binding, advisory basis, the holding of future advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 458989 11 ABSTAIN 458989 AGAINST 2 COMPASS THERAPEUTICS, INC. 20454B104 US20454B1044 06/10/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 753734 137266 ABSTAIN 753734 AGAINST 1 COMPASS THERAPEUTICS, INC. 20454B104 US20454B1044 06/10/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 753734 137266 ABSTAIN 753734 AGAINST 2 COMPASS THERAPEUTICS, INC. 20454B104 US20454B1044 06/10/2026 To approve, on a non-binding, advisory basis, the holding of future advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 753734 137266 ABSTAIN 753734 AGAINST 1 COMPASS THERAPEUTICS, INC. 20454B104 US20454B1044 06/10/2026 To approve, on a non-binding, advisory basis, the holding of future advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 753734 137266 ABSTAIN 753734 AGAINST 2 CULLINAN THERAPEUTICS, INC. 230031106 US2300311063 06/16/2026 Proposal to vote, on an advisory basis, to approve our named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 102000 0 FOR 102000 FOR 1 CULLINAN THERAPEUTICS, INC. 230031106 US2300311063 06/16/2026 Proposal to vote, on an advisory basis, to approve our named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 102000 0 FOR 102000 FOR 2 CULLINAN THERAPEUTICS, INC. 230031106 US2300311063 06/16/2026 Proposal to vote, on an advisory basis, to approve our named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 198000 0 FOR 198000 FOR 1 CULLINAN THERAPEUTICS, INC. 230031106 US2300311063 06/16/2026 Proposal to vote, on an advisory basis, to approve our named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 198000 0 FOR 198000 FOR 2 IMMUNOVANT, INC. 45258J102 US45258J1025 08/27/2025 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 86518 0 FOR 86518 FOR 1 IMMUNOVANT, INC. 45258J102 US45258J1025 08/27/2025 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 86518 0 FOR 86518 FOR 2 IMMUNOVANT, INC. 45258J102 US45258J1025 08/27/2025 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 175658 0 FOR 175658 FOR 1 IMMUNOVANT, INC. 45258J102 US45258J1025 08/27/2025 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 175658 0 FOR 175658 FOR 2 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. MARK PRUZANSKI IN HIS CAPACITY AS CHAIRMAN OF THE BOARD OF DIRECTORS FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 565081 0 FOR 565081 FOR 1 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. MARK PRUZANSKI IN HIS CAPACITY AS CHAIRMAN OF THE BOARD OF DIRECTORS FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 565081 0 FOR 565081 FOR 2 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. FREDERIC CREN IN HIS CAPACITY AS CHIEF EXECUTIVE OFFICER UNTIL SEPTEMBER 30, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 565081 0 FOR 565081 FOR 1 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. FREDERIC CREN IN HIS CAPACITY AS CHIEF EXECUTIVE OFFICER UNTIL SEPTEMBER 30, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 565081 0 FOR 565081 FOR 2 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. ANDREW OBENSHAIN IN HIS CAPACITY AS CHIEF EXECUTIVE OFFICER FROM OCTOBER 1ST, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 565081 0 FOR 565081 FOR 1 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. ANDREW OBENSHAIN IN HIS CAPACITY AS CHIEF EXECUTIVE OFFICER FROM OCTOBER 1ST, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 565081 0 FOR 565081 FOR 2 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. PIERRE BROQUA IN HIS CAPACITY AS DEPUTY CHIEF EXECUTIVE OFFICER UNTIL JUNE 30, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 565081 0 FOR 565081 FOR 1 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. PIERRE BROQUA IN HIS CAPACITY AS DEPUTY CHIEF EXECUTIVE OFFICER UNTIL JUNE 30, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 565081 0 FOR 565081 FOR 2 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. MARK PRUZANSKI IN HIS CAPACITY AS CHAIRMAN OF THE BOARD OF DIRECTORS FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 1096920 0 FOR 1096920 FOR 1 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. MARK PRUZANSKI IN HIS CAPACITY AS CHAIRMAN OF THE BOARD OF DIRECTORS FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 1096920 0 FOR 1096920 FOR 2 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. FREDERIC CREN IN HIS CAPACITY AS CHIEF EXECUTIVE OFFICER UNTIL SEPTEMBER 30, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 1096920 0 FOR 1096920 FOR 1 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. FREDERIC CREN IN HIS CAPACITY AS CHIEF EXECUTIVE OFFICER UNTIL SEPTEMBER 30, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 1096920 0 FOR 1096920 FOR 2 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. ANDREW OBENSHAIN IN HIS CAPACITY AS CHIEF EXECUTIVE OFFICER FROM OCTOBER 1ST, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 1096920 0 FOR 1096920 FOR 1 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. ANDREW OBENSHAIN IN HIS CAPACITY AS CHIEF EXECUTIVE OFFICER FROM OCTOBER 1ST, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 1096920 0 FOR 1096920 FOR 2 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. PIERRE BROQUA IN HIS CAPACITY AS DEPUTY CHIEF EXECUTIVE OFFICER UNTIL JUNE 30, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 1096920 0 FOR 1096920 FOR 1 INVENTIVA SA F5R343107 FR0013233012 06/30/2026 FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. PIERRE BROQUA IN HIS CAPACITY AS DEPUTY CHIEF EXECUTIVE OFFICER UNTIL JUNE 30, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 1096920 0 FOR 1096920 FOR 2 MOONLAKE IMMUNOTHERAPEUTICS 61559X104 KY61559X1045 06/04/2026 Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 170000 0 FOR 170000 FOR 1 MOONLAKE IMMUNOTHERAPEUTICS 61559X104 KY61559X1045 06/04/2026 Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 170000 0 FOR 170000 FOR 2 MOONLAKE IMMUNOTHERAPEUTICS 61559X104 KY61559X1045 06/04/2026 Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 330000 0 FOR 330000 FOR 1 MOONLAKE IMMUNOTHERAPEUTICS 61559X104 KY61559X1045 06/04/2026 Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 330000 0 FOR 330000 FOR 2 NEKTAR THERAPEUTICS 640268306 US6402683063 06/04/2026 To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote). SECTION 14A SAY-ON-PAY VOTES ISSUER 93500 0 FOR 93500 FOR 1 NEKTAR THERAPEUTICS 640268306 US6402683063 06/04/2026 To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote). SECTION 14A SAY-ON-PAY VOTES ISSUER 93500 0 FOR 93500 FOR 2 NEKTAR THERAPEUTICS 640268306 US6402683063 06/04/2026 To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote). SECTION 14A SAY-ON-PAY VOTES ISSUER 181500 0 FOR 181500 FOR 1 NEKTAR THERAPEUTICS 640268306 US6402683063 06/04/2026 To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote). SECTION 14A SAY-ON-PAY VOTES ISSUER 181500 0 FOR 181500 FOR 2 NEUROGENE INC. 64135M105 US64135M1053 06/03/2026 To approve on an advisory (non-binding) basis the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 170000 0 FOR 170000 FOR 1 NEUROGENE INC. 64135M105 US64135M1053 06/03/2026 To approve on an advisory (non-binding) basis the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 170000 0 FOR 170000 FOR 2 NEUROGENE INC. 64135M105 US64135M1053 06/03/2026 To hold a non-binding advisory vote on whether future non-binding advisory votes on the executive compensation paid by the company to its named executive officers should be held every one, two, or three years. SECTION 14A SAY-ON-PAY VOTES ISSUER 170000 0 1 YEAR 170000 FOR 1 NEUROGENE INC. 64135M105 US64135M1053 06/03/2026 To hold a non-binding advisory vote on whether future non-binding advisory votes on the executive compensation paid by the company to its named executive officers should be held every one, two, or three years. SECTION 14A SAY-ON-PAY VOTES ISSUER 170000 0 1 YEAR 170000 FOR 2 NEUROGENE INC. 64135M105 US64135M1053 06/03/2026 To approve on an advisory (non-binding) basis the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 330000 0 FOR 330000 FOR 1 NEUROGENE INC. 64135M105 US64135M1053 06/03/2026 To approve on an advisory (non-binding) basis the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 330000 0 FOR 330000 FOR 2 NEUROGENE INC. 64135M105 US64135M1053 06/03/2026 To hold a non-binding advisory vote on whether future non-binding advisory votes on the executive compensation paid by the company to its named executive officers should be held every one, two, or three years. SECTION 14A SAY-ON-PAY VOTES ISSUER 330000 0 1 YEAR 330000 FOR 1 NEUROGENE INC. 64135M105 US64135M1053 06/03/2026 To hold a non-binding advisory vote on whether future non-binding advisory votes on the executive compensation paid by the company to its named executive officers should be held every one, two, or three years. SECTION 14A SAY-ON-PAY VOTES ISSUER 330000 0 1 YEAR 330000 FOR 2 OPUS GENETICS, INC. 67577R102 US67577R1023 04/20/2026 Approval, on an advisory basis, of the compensation of the Company's named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 110276 0 FOR 110276 FOR 1 OPUS GENETICS, INC. 67577R102 US67577R1023 04/20/2026 Approval, on an advisory basis, of the compensation of the Company's named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 110276 0 FOR 110276 FOR 2 OPUS GENETICS, INC. 67577R102 US67577R1023 04/20/2026 Approval, on an advisory basis, of the compensation of the Company's named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 214064 0 FOR 214064 FOR 1 OPUS GENETICS, INC. 67577R102 US67577R1023 04/20/2026 Approval, on an advisory basis, of the compensation of the Company's named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 214064 0 FOR 214064 FOR 2 ORUKA THERAPEUTICS, INC. 687604108 US6876041087 06/02/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 56832 0 FOR 56832 FOR 1 ORUKA THERAPEUTICS, INC. 687604108 US6876041087 06/02/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 56832 0 FOR 56832 FOR 2 ORUKA THERAPEUTICS, INC. 687604108 US6876041087 06/02/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 126498 0 FOR 126498 FOR 1 ORUKA THERAPEUTICS, INC. 687604108 US6876041087 06/02/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 126498 0 FOR 126498 FOR 2 PALISADE BIO, INC. 696389402 US6963894026 06/10/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 1157957 0 FOR 1157957 FOR 1 PALISADE BIO, INC. 696389402 US6963894026 06/10/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 1157957 0 FOR 1157957 FOR 2 PALISADE BIO, INC. 696389402 US6963894026 06/10/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 2247800 0 FOR 2247800 FOR 1 PALISADE BIO, INC. 696389402 US6963894026 06/10/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 2247800 0 FOR 2247800 FOR 2 REZOLUTE, INC. 76200L309 US76200L3096 11/19/2025 To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Executive Compensation section of the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 760060 0 FOR 760060 FOR 1 REZOLUTE, INC. 76200L309 US76200L3096 11/19/2025 To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Executive Compensation section of the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 760060 0 FOR 760060 FOR 2 REZOLUTE, INC. 76200L309 US76200L3096 11/19/2025 To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Executive Compensation section of the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 1691749 0 FOR 1691749 FOR 1 REZOLUTE, INC. 76200L309 US76200L3096 11/19/2025 To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Executive Compensation section of the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 1691749 0 FOR 1691749 FOR 2 SCYNEXIS, INC. 811292200 US8112922005 06/25/2026 To vote, on an advisory basis, on the compensation paid to SCYNEXIS's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 2568478 0 FOR 2568478 FOR 1 SCYNEXIS, INC. 811292200 US8112922005 06/25/2026 To vote, on an advisory basis, on the compensation paid to SCYNEXIS's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 2568478 0 FOR 2568478 FOR 2 SCYNEXIS, INC. 811292200 US8112922005 06/25/2026 To vote, on an advisory basis, on the frequency of future advisory voting on the compensation paid to SCYNEXIS's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 2568478 0 1 YEAR 2568478 FOR 1 SCYNEXIS, INC. 811292200 US8112922005 06/25/2026 To vote, on an advisory basis, on the frequency of future advisory voting on the compensation paid to SCYNEXIS's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 2568478 0 1 YEAR 2568478 FOR 2 SCYNEXIS, INC. 811292200 US8112922005 06/25/2026 To vote, on an advisory basis, on the compensation paid to SCYNEXIS's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 4985869 0 FOR 4985869 FOR 1 SCYNEXIS, INC. 811292200 US8112922005 06/25/2026 To vote, on an advisory basis, on the compensation paid to SCYNEXIS's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 4985869 0 FOR 4985869 FOR 2 SCYNEXIS, INC. 811292200 US8112922005 06/25/2026 To vote, on an advisory basis, on the frequency of future advisory voting on the compensation paid to SCYNEXIS's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 4985869 0 1 YEAR 4985869 FOR 1 SCYNEXIS, INC. 811292200 US8112922005 06/25/2026 To vote, on an advisory basis, on the frequency of future advisory voting on the compensation paid to SCYNEXIS's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 4985869 0 1 YEAR 4985869 FOR 2 SILENCE THERAPEUTICS PLC 82686Q101 US82686Q1013 06/16/2026 To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 346967 0 FOR 346967 FOR 1 SILENCE THERAPEUTICS PLC 82686Q101 US82686Q1013 06/16/2026 To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 346967 0 FOR 346967 FOR 2 SILENCE THERAPEUTICS PLC 82686Q101 US82686Q1013 06/16/2026 To approve our directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the proxy statement and on pages 32 to 54 of the 2025 U.K. Annual Report). SECTION 14A SAY-ON-PAY VOTES ISSUER 346967 0 FOR 346967 FOR 1 SILENCE THERAPEUTICS PLC 82686Q101 US82686Q1013 06/16/2026 To approve our directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the proxy statement and on pages 32 to 54 of the 2025 U.K. Annual Report). SECTION 14A SAY-ON-PAY VOTES ISSUER 346967 0 FOR 346967 FOR 2 SILENCE THERAPEUTICS PLC 82686Q101 US82686Q1013 06/16/2026 To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 673522 0 FOR 673522 FOR 1 SILENCE THERAPEUTICS PLC 82686Q101 US82686Q1013 06/16/2026 To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 673522 0 FOR 673522 FOR 2 SILENCE THERAPEUTICS PLC 82686Q101 US82686Q1013 06/16/2026 To approve our directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the proxy statement and on pages 32 to 54 of the 2025 U.K. Annual Report). SECTION 14A SAY-ON-PAY VOTES ISSUER 673522 0 FOR 673522 FOR 1 SILENCE THERAPEUTICS PLC 82686Q101 US82686Q1013 06/16/2026 To approve our directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the proxy statement and on pages 32 to 54 of the 2025 U.K. Annual Report). SECTION 14A SAY-ON-PAY VOTES ISSUER 673522 0 FOR 673522 FOR 2 ULTRAGENYX PHARMACEUTICAL INC. 90400D108 US90400D1081 05/14/2026 Advisory (non-binding) vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 NONE 0 NONE 1 ULTRAGENYX PHARMACEUTICAL INC. 90400D108 US90400D1081 05/14/2026 Advisory (non-binding) vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 NONE 0 NONE 2 ULTRAGENYX PHARMACEUTICAL INC. 90400D108 US90400D1081 05/14/2026 Advisory (non-binding) vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 NONE 0 NONE 1 ULTRAGENYX PHARMACEUTICAL INC. 90400D108 US90400D1081 05/14/2026 Advisory (non-binding) vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 NONE 0 NONE 2 VERA THERAPEUTICS, INC. 92337R101 US92337R1014 05/21/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 67778 0 FOR 67778 FOR 1 VERA THERAPEUTICS, INC. 92337R101 US92337R1014 05/21/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 67778 0 FOR 67778 FOR 2 VERA THERAPEUTICS, INC. 92337R101 US92337R1014 05/21/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 131570 0 FOR 131570 FOR 1 VERA THERAPEUTICS, INC. 92337R101 US92337R1014 05/21/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 131570 0 FOR 131570 FOR 2